Proactive Investors - Run By Investors For Investors

OptiBiotix inks Thai deal for weight-loss product

The exclusive agreement with Primo Trading opens up a new Asian market for the SlimBiome product
obese man
There is a growing obesity crisis in the developing world

OptiBiotix Health PLC (LON:OPTI) has signed an exclusive distribution deal for its weight loss product in Thailand.

The three-year agreement with Primo Trading will see the Thai company buy a minimum of 500kg of SlimBiome in the first 12 months, rising to 5,000kg by year-three. It has already made an initial 100kg purchase.

The product appears to be gaining commercial traction in Asia with approval in India opening the way for sales into one of the region’s largest markets.

“The growing obesity crisis has opened up an opportunity in these markets for SlimBiome where food supplements and functional holistic products are readily accepted,” said Christina Wood, sales and marketing director at OptiBiotix.”

Thailand, for example, is experiencing an obesity wave with one in three men and 40% of women now classified as overweight. The country is now the second heaviest in Asia after Malaysia, mainly as a result of increasing fast food outlets and high sugar usage throughout the food industry.

Wood went on: “The value gained from our industry awards, clinical studies and recent medical device approval has given our products clear differentiation over other weight loss products.

“The team at Primo have already identified key areas for SlimBiome and are in the process of formulating SlimBiome containing products to meet local tastes.”

OptiBiotix’s discoveries focus on gut health and the growing realisation that changes to the human microbiome are able improve health. As well as weight-loss products it is developing compounds to treat diabetes and high cholesterol.

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use